Evidence map›Paper›PMID 36657980›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Toward Single-Time-Point Image-Based Dosimetry of

Julia Brosch-Lenz, Astrid Delker, Friederike Völter, Lena M Unterrainer, Lena Kaiser, Peter Bartenstein, Sibylle Ziegler, Arman Rahmim, Carlos Uribe, Guido Böning

Open access · hybridAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 70 citations in OpenAlex.

  1. Phase 2 Prospective Trial of Retreatment with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Trial
  2. Metformin and renal dosimetry in patients undergoing [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  4. Outcome-driven dosimetry optimization for [European journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Article
  6. Article
  7. Applications of artificial intelligence in nuclear medicine.Zeitschrift fur medizinische Physik · 2026
    Review
  8. Review
  9. Clinical value of per-treatment whole-body single-time-point automated dosimetry for [European journal of nuclear medicine and molecular imaging · 2026
    Article
  10. OptimizingNuclear medicine and molecular imaging · 2026
    Article
  11. Review
  12. Article
  13. Fast [EJNMMI physics · 2026
    Article
  14. Review
  15. Review
  16. Future of radiotheranostics.BMJ oncology · 2026
    Review
  17. Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  18. Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Julia Brosch-LenzDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; jbrosch@bccrc.ca.
Astrid DelkerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Friederike VölterDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Lena M UnterrainerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Lena KaiserDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Peter BartensteinDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Sibylle ZieglerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Arman RahmimDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada.
Carlos UribeDepartment of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.
Guido BöningDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
LMU Klinikum · DEUniversity of British Columbia · CALudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiopharmaceutical therapies (RPTs) with

Indexed as

Prostatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingHumansLutetiumMaleProstate-Specific AntigenRadiopharmaceuticalsDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstate-Specific AntigenPSMA-617Radiopharmaceuticals177LuPSMA therapysingle-time-point dosimetry

Identifiers

PMID36657980
PMCPMC10152120
OpenAlexW4317515968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.